Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
about
Immunoregulatory functions of immune complexes in vaccine and therapyDirect Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future TherapiesTherapeutic cancer vaccines: past, present, and futureDendritic cell-based vaccination in cancer: therapeutic implications emerging from murine modelsPros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesTargeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective ImmunityDendritic cell-based vaccine efficacy: aiming for hot spotsLumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine developmentHuman XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells.Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein.Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.Antigen targeting to dendritic cells allows the identification of a CD4 T-cell epitope within an immunodominant Trypanosoma cruzi antigenThe Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases.Surface display of an anti-DEC-205 single chain Fv fragment in Lactobacillus plantarum increases internalization and plasmid transfer to dendritic cells in vitro and in vivoInduction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptorTargeting dendritic cells in situ for breast cancer immunotherapy.Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.Preclinical HER-2 Vaccines: From Rodent to Human HER-2The immune system and inflammation in breast cancer.Targeted antigen delivery to DEC-205⁺ dendritic cells for tolerogenic vaccinationThe presence of T cell epitopes is important for induction of antibody responses against antigens directed to DEC205+ dendritic cells.Non-invasive administration of biodegradable nano-carrier vaccines.A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Targeting antigens to dendritic cell receptors for vaccine developmentBiomarker discovery of nasopharyngeal carcinoma by proteomics.Dendritic cell-based vaccines: clinical applications in breast cancer.Targeting human dendritic cells in situ to improve vaccines.Application of arteether-loaded polyurethane nanomicelles to induce immune response in breast cancer model.Mouse models in oncoimmunology.YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage.Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells.Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.Enhanced Humoral Responses Induced by Targeting of Antigen to Murine Dendritic Cells.Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer.Dendritic cell immunotherapy.Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.Association between inflammation and cancer stem cell phenotype in breast cancer.
P2860
Q26738396-D3199582-0EDA-4719-8635-B36C5B1FDC3FQ26752558-6A29CC5B-C7EB-48CF-A507-FCD085CA0CD3Q26863283-5ABCD6A5-00A3-4117-8560-123F918043DFQ27012618-BBA7765D-7659-427F-ABDD-3661E77D58B9Q27013679-A172B193-5B45-433F-B450-C5603975F2E5Q27312070-95244988-51DE-4245-A76F-638F41C14D79Q28082680-DBB5F927-59DC-4529-AB61-ACBCB15DD546Q33850508-CA633F0B-4604-4B15-8A8C-B61226BBCB8CQ33998442-3BFF23BE-A7E7-487E-8ACE-0B257BEC64FCQ34364276-DBA79E5E-4E0E-4E81-92E4-D275A9D8FDE4Q34406488-C7E038F6-D3AD-4C1F-95D9-D9CD3178C9C2Q35095495-50B65509-8388-4148-8AA5-75C0DAE55080Q35739662-F22DC255-E3E9-4400-A1F9-0AEECD566124Q35816760-D632A291-0751-49E8-AF43-D70363D9C1E8Q36288336-DD6204FD-8613-4991-B8F4-556F9F88D131Q36456497-860BBDB7-B737-43CF-9703-644AFCA67BE8Q36498243-4D5AA4D1-97BC-40D1-9193-03CC46EDA338Q36864003-30DD9FF8-AC78-4109-809B-EF6C628DBF2CQ36914661-FF50AC87-A3BD-42FE-862B-7D125EA18B8EQ37033451-1F376738-6B1D-4A84-A0DF-87C0EF638FB3Q37088207-38857304-57BE-4825-9DBE-B265D5F15BF9Q37522784-F8523110-844E-44A3-A5E6-6AA982F6236CQ37596856-2649EC88-18CA-4CD5-94AA-57E02E847CB8Q37619840-49468BCC-FDD1-4E59-9D92-F6D77D7191B7Q38076053-68EA28D8-9A9D-4197-A17E-DFEBA4D260C5Q38162446-0D835AF1-93C2-4CEB-BB82-57BE37CCC93EQ38194579-773EC5C6-592F-4640-81BA-B21BEF0211FAQ38206821-8337E1DF-36F1-475F-ACB3-0812E6B50A01Q38235001-B4A31195-9E31-4779-9437-61FE2E446E9FQ38766425-1416FA18-A2F8-4E06-B544-85EBA5CCA3C8Q38968582-9AB48509-C97B-40CF-A42B-555387B7EE2FQ39241485-A80960EC-ADC0-405F-99E9-B01043816A01Q39559063-36ACF6C0-F1D5-4442-9BF0-310A31C7B759Q40452198-84F401B1-147F-48F9-9F0C-CE034626A4CFQ40565323-49787ECB-43CC-470C-8145-3B15B8FE927FQ42326285-58633A83-52E9-4F41-9ADC-B70C2F0D8E32Q42753871-981E066D-600E-4FF1-AFFC-DEF2C150B839Q44483910-6D62FB6D-B434-45D6-A088-110DE2472566Q45862822-5CBF10A2-2316-4B5E-8DC1-B8471AB88AB5Q49704531-0FD4D6CB-933D-4442-A4E3-7A0909556922
P2860
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting of the non-mutated t ...... against breast cancer in mice.
@ast
Targeting of the non-mutated t ...... against breast cancer in mice.
@en
type
label
Targeting of the non-mutated t ...... against breast cancer in mice.
@ast
Targeting of the non-mutated t ...... against breast cancer in mice.
@en
prefLabel
Targeting of the non-mutated t ...... against breast cancer in mice.
@ast
Targeting of the non-mutated t ...... against breast cancer in mice.
@en
P2093
P2860
P356
P1476
Targeting of the non-mutated t ...... against breast cancer in mice.
@en
P2093
Janelle M Y Kuroiwa
Li-Zhen He
Neeha Zaidi
Ralph M Steinman
Tibor Keler
P2860
P2888
P356
10.1186/BCR3135
P577
2012-03-07T00:00:00Z
P5875
P6179
1031575523